Durable remission of metastatic myxoid liposarcoma following the cautious addition of pembrolizumab to ongoing pazopanib treatment: A case report
Hussain Abbas, Wolfram Samlowski, Amin Hedayat · 2026
Read Durable remission of metastatic myxoid liposarcoma following the cautious addition of pembrolizumab to ongoing pazopanib treatment: A case report by Hussain Abbas, Wolfram Samlowski, Amin Hedayat (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13180121.txt.
Description
Abbas, Samlowski, and Hedayat report a single cancer case in twenty twenty-six. The patient had a rare fat tissue cancer that had spread to other sites. Such spread cancers in soft tissue often respond poorly to standard drugs. Responses, when they occur, tend to be brief.
The team added a drug called pembrolizumab to a drug the patient already took, pazopanib. This was the fourth line of treatment tried. The tumors shrank a lot after just five doses, with little harm from side effects. After fifteen doses, scans showed the response held, and a biopsy found no live cancer in a sampled lesion. The patient then stopped all treatment and stayed in remission. The authors suggest the pair merits more study.
Catalog record
| CREATOR | Hussain Abbas, Wolfram Samlowski, Amin Hedayat |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |